The Comprehensive Digestive Stool Analysis 2.0™ (CDSA 2.0) is an advanced stool test that provides immediate, actionable clinical information for the management of gastrointestinal health. Utilizing cutting-edge technologies and biomarkers, this test offers valuable insight into digestive function, intestinal inflammation, and the intestinal microbiome.
The biomarkers from the CDSA 2.0 Profile are reported using the DIG framework, providing key clinical information for three main gastrointestinal functional areas:
The CDSA 2.0 Profile can reveal important information about the root cause of many common gastrointestinal symptoms such as gas, bloating, indigestion, abdominal pain, diarrhea, and constipation. This stool analysis utilizes biomarkers such as Calprotectin to differentiate between Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS).1,2 In addition, Genova's CDSA 2.0 test can be used to evaluate patients with a clinical history that suggests a gastrointestinal infection or dysbiosis.
A structured fecal biomarker panel offers the advantage of assessing multiple functional areas that may be contributing to symptoms. For example, diarrhea could stem from multiple causes including pancreatic exocrine insufficiency, inflammation, food allergies, or the presence of a pathogenic or potentially pathogenic organism. A positive result on one or more fecal biomarker tests may guide therapy, either by suggesting a treatable alternative diagnosis or by eliminating a diagnosis from further consideration. The latter allows individualized targeted treatment to be redirected to more likely diagnoses.3,4
CDSA 2.0 represents the best technical platform to assess gut health, including Matrix Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) technology for cultivable species identification, as well as stool-based biomarkers for gastrointestinal diagnostics.
The CDSA 2.0 Profile biomarkers provide comprehensive information for the development of strategic interventions. Symptoms often improve as identified functional imbalances and inadequacies become normalized through targeted dietary, lifestyle, and supplementation therapeutics.
Test Type: Stool Analysis
Analyte List |
---|
Bacteriology Culture, aerobic |
Bacteriology Culture, aerobic x 3 |
Bacteriology Culture, anaerobic |
Beneficial SCFAs |
Beta-Glucuronidase |
Calprotectin |
Deoxycholic Acid |
Entamoeba histolytica |
Eosinophil Protein X (EPX) |
LithoCholic Acid |
Pancreatic Elastase |
Parasite Identification, Concentrate Prep |
Parasite Identification, Trichrome Stain |
Putrefactive SCFAs |
Yeast Culture |
n-Butyrate % |
pH |
CPT Codes | |
---|---|
Bacteriology Culture, aerobic | 87045 |
Bacteriology Culture, aerobic x 3 | 87046 |
Bacteriology Culture, anaerobic | 87075 |
Beneficial SCFAs | 82542 |
Beta-Glucuronidase | 84311 |
Calprotectin | 83993 |
Entamoeba histolytica | 87336 |
Eosinophil Protein X (EPX) | 83520 |
Pancreatic Elastase | 82656 |
Parasite Identification, Concentrate Prep | 87177 |
Parasite Identification, Trichrome Stain | 87209 |
Yeast Culture | 87102 |
pH | 83986 |
Specimen Requirements |
---|
5cc stool in each vial - 3 SAF, 1 Cary Blair, 1 Formalin; 40ml stool in white-top cup. May be random stool or purge. |